Beschreibung
Both empagliflozin and furosemide promote natriuresis and diuresis; concurrent use can produce additive volume depletion, hypotension, and electrolyte disturbances.
Mechanismus
Empagliflozin inhibits SGLT2 in the proximal tubule, causing glucosuria, natriuresis, and osmotic diuresis; furosemide blocks the Na-K-2Cl transporter in the loop of Henle. Combined diuretic effects can cause dehydration and orthostatic hypotension.
Klinische Bedeutung
Clinical trials and post-marketing data show increased rates of volume depletion-related adverse events (hypotension, dizziness, acute kidney injury) with SGLT2 inhibitor and loop diuretic combinations, especially in elderly patients.
Maßnahmen
Assess volume status before and after initiating empagliflozin in patients on loop diuretics; consider dose reduction of furosemide; monitor blood pressure, renal function, and electrolytes closely.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.